Uncategorized

Regulators overseeing rare disease treatments need better tools to weigh competing risks in real time. Sarepta Therapeutics’ Elevidys is a prime example of why.

LB Pharma needed $350 million to advance a promising schizophrenia candidate at a time when the biotech markets were locked up tight. Fortunately, it wasn’t CEO Heather Turner’s first rodeo.

The Dexcom CEO will lead the lobbying group’s sector representing diabetes tech companies around the world.

Taking an early proof of concept into preclinical and clinical development is a costly and complex process. But there are strategic ways to streamline the process and reduce risk and costs. In this webinar, you’ll hear directly from Nobel Laureate Sir Michael Houghton and experts from Applied Pharma, who bring decades of real-world success and

The deal, which will take Enhabit private, comes after private equity investments in healthcare reached record highs last year.

CEO Scott Whitaker said the medtech lobbying group stands ready to work with President Donald Trump to address trade imbalances by confronting unfair foreign practices in the sector.

The company plans to divest a drug it has made for 40 years, citing increasing production costs and falling prices.

The diabetes spinoff plans to offer 28 million shares at $25 to $28 each.

Congressional scorekeepers expect the Hospital Insurance trust fund to run dry more than a decade earlier than they previously expected, after Republicans’ megabill slashed the revenues it receives from taxes.

The workers’ union said “significant movement” at the bargaining table led to the end of the strike. Kaiser said union leadership accepted the health system’s wage increase it offered in October.